AMARILLO, TX--(Marketwire - July 19, 2011) -
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR
) today announced that it has formed an alliance with Bio-Stasis International, Inc., a dietary supplement internet marketer, to launch Bio-Stasis International's Virapress. Bio-Stasis plans to embark on an extensive internet marketing program for Virapress on August 1, 2011, targeting alternative and complimentary medical practitioners.
Virapress is a dietary supplement derived from a bovine protein extract produced by ABI and will be marketed with claims to improve health and enhance immunity. In parallel with Bio-Stasis International's internet marketing campaign, ABI will market its bovine extract to health food stores and internationally under ABI's brand name. ABI has already received serious inquiries about distribution rights from marketers in 9 different countries in the Middle East and Africa and has commenced negotiations on international distribution rights.
"We expect our internet marketing campaign to significantly increase the market for Virapress and, also, its primary ingredient, bovine extract," said Lawrence H. Griffin, president, Bio-Stasis International.
Virapress has not been evaluated by the Food and Drug Administration, and should not take the place of a regular medical evaluation by a licensed health practitioner.
About Bio-Stasis International, Inc.
Bio-Stasis is committed to the promotion of natural products which have been shown to promote health and healing. Each Bio-Stasis product must have scientific evidence to support effectiveness, without side effects. For additional information, please visit the Bio-Stasis International Inc.'s website www.virapress.com
About Amarillo Biosciences
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 6% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web at http://www.amarbio.com/.
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" and "Item 7A. Qualitative and Quantitative Disclosures About Market Risk" of the Company's Form 10-K for the fiscal year ended December 31, 2010.